Biotechnology

Tenaya Therapeutics seeks fresh capital to advance its heart disease pipeline, but the offering's structure raises dilution questions for investors.

A routine filing reveals a major strategic play. See how BridgeBio Oncology uses special equity grants to attract top minds in the fierce race for a cancer cure.

Tevogen CEO's $100k stock gift to local police offers a case study in ESG, community engagement, and the strategic value of corporate social responsibility.

A regulatory filing reveals a key investor's move in the Avadel bidding war, exposing the intense M&A hunger driving the future of health tech.

In a market tired of hype, investors are rewarding verifiable results. We explore the tech delivering hard proof, from quantum security to cancer therapies.

A startup's legal victory protects its revolutionary wound care tech derived from the axolotl, paving the way for a new era in regenerative medicine.

A new contract for its explainable AI in a pivotal Phase 3 trial shows NetraMark is helping Big Pharma de-risk its most expensive R&D phase.

Early results for INT230-6 show 50% fewer severe side effects, raising hopes for a treatment that could eliminate the toxic 'red devil' chemo.

Adagio Medical lands ex-Medtronic exec Sean Salmon. His mission: drive its novel cryoablation tech to disrupt the competitive cardiac arrhythmia market.

Beyond services, Charles River is building an ecosystem. We look at how its incubator nurtures startups and secures its own future in advanced medicine.

Polyrizon's novel hydrogel shows it can stick to nasal tissue longer without slowing drug delivery, a key innovation in the fight against opioid overdose.

New Phase 2 data shows Elicio's off-the-shelf therapy ELI-002 7P induces "antigen spreading," creating a personalized anti-tumor response.

Cadrenal Therapeutics acquires a novel Phase 2 drug for a deadly clotting disorder, a strategic move targeting an underserved $1 billion market.

A tech-driven 'anti-CRO' and a clinical accelerator have joined forces. Can their integrated model finally fix the broken drug development pipeline?

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

Praxis Precision Medicines secures a clear path to market for its rare epilepsy drug, blending genetic science with a savvy regulatory strategy.

A new 24g wearable device promises clinic-grade laser therapy for just $99. Can its high-power science truly democratize healing, or is it just hype?

Abeona Therapeutics' new treatment center for ZEVASKYN marks a strategic leap in gene therapy access, but what does it mean for patients and the market?

A once-failed class of weight-loss drugs is back with a new design. Corbus Pharma's early data suggests it may have solved the safety puzzle.

After a decade of failed trials, a new drug shows promise in treating resistant lung cancer by reawakening the immune system and halting its spread.